NCT01896583

A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety and Tolerability, of ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Seldar Pharma, Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial will evaluate the effect of ASP7147 on daily abdominal pain due to IBS-D during 4 weeks of treatment. It will also evaluate safety and tolerability in patients with IBS-D over the 4-week treatment period.

Conditions

• Diarrhea Predominant Irritable Bowel Syndrome

Interventions

Type	Name	Description
DRUG	ASP7147	300 mg, tablet, twice per day for 4 weeks oral
DRUG	Placebo

Timeline

• Start date: 2013-11-01
• Primary completion: 2014-03-01
• Completion: 2014-07-01
• First posted: 2013-07-11
• Last updated: 2019-06-06

Locations

13 sites across 1 country: United States